Updates are available Correction dated 2022-12-23
Click to view Correction: https://doi.org/10.1038/s41467-022-35644-0
-
Authors
Warrick, Joshua I. https://orcid.org/0000-0001-6149-1331
Hu, Wenhuo https://orcid.org/0000-0002-8686-7160
Yamashita, Hironobu
Walter, Vonn https://orcid.org/0000-0001-6114-6714
Shuman, Lauren https://orcid.org/0000-0003-2383-2240
Craig, Jenna M.
Gellert, Lan L.
Castro, Mauro A. A.
Robertson, A. Gordon
Kuo, Fengshen https://orcid.org/0000-0003-1797-2896
Ostrovnaya, Irina
Sarungbam, Judy
Chen, Ying-bei https://orcid.org/0000-0001-5207-3648
Gopalan, Anuradha
Sirintrapun, Sahussapont J.
Fine, Samson W. https://orcid.org/0000-0002-4322-3736
Tickoo, Satish K. https://orcid.org/0000-0002-9775-0478
Kim, Kwanghee https://orcid.org/0000-0003-0544-6792
Thomas, Jasmine
Karan, Nagar
Gao, Sizhi Paul
Clinton, Timothy N. https://orcid.org/0000-0002-0616-6840
Lenis, Andrew T. https://orcid.org/0000-0001-9413-7793
Chan, Timothy A. https://orcid.org/0000-0002-9265-0283
Chen, Ziyu https://orcid.org/0000-0002-1198-1516
Rao, Manisha
Hollman, Travis J. https://orcid.org/0000-0003-1599-0433
Li, Yanyun
Socci, Nicholas D.
Chavan, Shweta
Viale, Agnes
Mohibullah, Neeman
Bochner, Bernard H.
Pietzak, Eugene J.
Teo, Min Yuen https://orcid.org/0000-0003-2511-6731
Iyer, Gopa https://orcid.org/0000-0002-5093-6099
Rosenberg, Jonathan E.
Bajorin, Dean F. https://orcid.org/0000-0003-4001-7088
Kaag, Matthew
Merrill, Suzanne B.
Joshi, Monika
Adam, Rosalyn https://orcid.org/0000-0002-0943-6236
Taylor, John A. III
Clark, Peter E.
Raman, Jay D.
Reuter, Victor E.
Chen, Yu https://orcid.org/0000-0002-0171-3884
Funt, Samuel A. https://orcid.org/0000-0002-7235-6319
Solit, David B. https://orcid.org/0000-0002-6614-802X
DeGraff, David J. https://orcid.org/0000-0002-7154-7594
Al-Ahmadie, Hikmat A. https://orcid.org/0000-0002-2938-6627
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0916)
American Cancer Society (RSG 17-233-01-TBE)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA233899, P50CA221745, P30CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
The Albert Institute for Bladder Cancer Care and Research, Parker Institute for Cancer Immunotherapy, Cycle for Survival, the Mark Foundation.
- License Information
-
More Information
Article History
Received: 6 April 2021
Accepted: 19 October 2022
First Online: 2 November 2022
Change Date: 23 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-35644-0
Competing interests
: E.J.P. received honorarium from UpToDate, and received research funding from and is on the scientific advisory boards for Janssen Pharmaceuticals, Merck & Co. Inc., QED Therapeutics, UroGen Pharma and Steba Biotech. D.B.S. has consulted for/received honoraria from Pfizer, Loxo/Lilly Oncology, FORE Therapeutics, Vividion Therapeutics, Scorpion Therapeutics, Fog Pharma, and BridgeBio. D.J.D. received a research grant from Bristol-Myers-Squibb. H.A.A has consulted for Bristol-Myers-Squibb, AstraZeneca, Janssen Biotech, and Paige.ai. M.J. received research grant from AstraZeneca, Pfizer, and Eisai (drug only to Institution), and is on the advisory board for Seagen. J.S. is a consultant for Janssen Research & Development, LLC. S.A.F. received research support from AstraZeneca, Genentech/Roche, is a consultant/advisory board member for Merck and BioNTech, and owns stock/equity interest in Urogen, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, ByHeart, 76Bio, Vida Ventures, Inconovir, and Doximity. B.H.B is a consultant to Olympus corporation. D.F.B. reports personal fees from Bristol Myers Squibb and Merck; consulting/advisory role for Merck, Dragonfly Therapeutics, Fidia Farmaceutici S.p.A., and Bristol Myers Squibb Foundation; Travel/accommodations/expenses from Merck; and institutional research funding from Novartis, Merck, Bristol-Myers Squibb, AstraZeneca, Astellas Pharma, and Seattle Genetics/Astellas. Y.C. reports stock ownership in Oric Pharmaceuticals and sponsored Research from Foghorn Therapeutics. J.E.R is a Consultant for Seagen, Astellas, Bayer, AstraZeneca, QED Therapeutics, Merck, Genentech, Infinity, Gilead, Boehringer Ingelheim, Tyra, Mirati, Pfizer, EMD-Serono; reports sponsored research from Seagen, Astellas, Bayer, AstraZeneca, QED Therapeutics, Genentech; and received honoraria from Pfizer and EMD-Serono. The remaining authors declare no conflicts of interest.
